Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / CHRS - Week In Review: Zhaoke Signs $130 Million Deal For Vision-Improving Eyedrops

CHRS - Week In Review: Zhaoke Signs $130 Million Deal For Vision-Improving Eyedrops

Coherus BioSciences Inc.
  • Nanjing InxMed announced a $15 million B+ funding round to develop its novel therapies that target the stroma microenvironment and drug resistance for hard-to-treat solid tumors. InxMed will use the funds for US/China clinical trials of its lead drug, IN10018.
  • US-based Coherus Biosciences returned the US rights to market an Innovent Avastin biosimilar to Innovent, blaming the COVID-19 epidemic for slowing its development of the biosimilar.
  • Ascletis Pharma of Hangzhou was approved to start US trials of its in-licensed PD-L1 as an immune restoration/functional cure of AIDS (HIV-1).

For further details see:

Week In Review: Zhaoke Signs $130 Million Deal For Vision-Improving Eyedrops
Stock Information
Company Name: Coherus BioSciences Inc.
Stock Symbol: CHRS
Market: NASDAQ
Website: coherus.com
Menu
CHRS CHRS Quote CHRS Short CHRS News CHRS Articles CHRS Message Board
Get CHRS Alerts

News, Short Squeeze, Breakout and More Instantly...